Figure 2.
Possible main targets of pemafibrate in conditions of dyslipidemia resulting from visceral obesity, metabolic syndrome, and NAFLD/NASH. Modified from a Figure in Reference [34]. * Both ApoC-III and ANGPTL3 inhibit LPL activity. ⍐: Increase ⍗: Decrease.
